Homepage > Company > Media > Pharma News > 2021 > NICE Endorses AstraZeneca’s Tagrisso for NSCLC Patients With Specific Mutation

NICE Endorses AstraZeneca’s Tagrisso for NSCLC Patients With Specific Mutation

The UK’s National Institute for Health and Care Excellence (NICE) has said the Cancer Drugs Fund, part of the National Health Service, should offer AstraZeneca’s Tagrisso (osimertinib) for patients with non-small cell lung cancer (NSCLC).

NICE recommended the drug for people with early-stage NSCLC who have had prior surgery to remove a tumor and who suffer from epidermal growth factor receptor (EGFR) genetic mutations.

Tagrisso blocks the mutated EGFR protein which causes cancer growth and may also help shrink tumor size.

December 6, 2021

https://www.fdanews.com/

Read also

Pfizer touts Tukysa in front-line breast cancer after Phase III victory

Pfizer’s Tukysa (tucatinib) has enhanced patient outcomes when used as a maintenance therapy during a late-stage trial in breast cancer.

Telomir Pharmaceuticals reports new preclinical data on pancreatic cancer

Telomir Pharmaceuticals, Inc., a $54 million market cap biotech company whose stock has declined 11% in the past week

Компания 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Gene Therapy Protects Kidneys in Preclinical Model of Type 1 Diabetes

One in three people with type one diabetes will develop kidney damage during their lifetime, which can develop silently over many years, often going undetected until it becomes severe.